DG-041 | CAS# 861238-35-9 |EP3 receptor antagonist |MedKoo

MedKoo Cat#: 531761 | Name: DG-041

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

DG-041 is a potent and selective prostanoid EP3 receptor antagonist. It is a new target for inhibition of platelet function in atherothrombotic disease.

Chemical Structure

DG-041

CAS# 861238-35-9

Theoretical Analysis

MedKoo Cat#: 531761

Name: DG-041

CAS#: 861238-35-9

Chemical Formula: C23H15Cl4FN2O3S2

Exact Mass: 589.9262

Molecular Weight: 592.30

Elemental Analysis: C, 46.64; H, 2.55; Cl, 23.94; F, 3.21; N, 4.73; O, 8.10; S, 10.83

Price and Availability

Size	Price	Availability	Quantity
10mg	USD 350.00	2 Weeks
25mg	USD 650.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

DG-041; DG 041; DG041; DTSI

IUPAC/Chemical Name

(E)-3-[1-[(2,4-dichlorophenyl)methyl]-5-fluoro-3-methylindol-7-yl]-N-(4,5-dichlorothiophen-2-yl)sulfonylprop-2-enamide

InChi Key

BFBTVZNKWXWKNZ-HWKANZROSA-N

InChi Code

InChI=1S/C23H15Cl4FN2O3S2/c1-12-10-30(11-14-2-4-15(24)7-18(14)25)22-13(6-16(28)8-17(12)22)3-5-20(31)29-35(32,33)21-9-19(26)23(27)34-21/h2-10H,11H2,1H3,(H,29,31)/b5-3+

SMILES Code

O=C(NS(=O)(C1=CC(Cl)=C(Cl)S1)=O)/C=C/C2=CC(F)=CC3=C2N(CC4=CC=C(Cl)C=C4Cl)C=C3C

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

Potent and selective EP3 antagonist; antiplatelet and antithrombotic.

In vitro activity:

DG-041 antagonized the effects of sulprostone on platelet function. The effect of PGE(2) on platelet aggregation depended on the nature of the agonist and the concentration of PGE(2) used as a consequence of both pro-aggregatory effects via EP3 and anti-aggregatory effects via other receptors. DG-041 potentiated the protective effects of PGE(2) on platelet aggregation by inhibiting the pro-aggregatory effect via EP3 stimulation. Reference: Platelets. 2008 Dec;19(8):605-13. https://pubmed.ncbi.nlm.nih.gov/19012178/

In vivo activity:

Following the measurement of baseline blood pressure, 10 μg/kg sulprostone was administered IV via the jugular catheter which caused a rise in mean arterial pressure (MAP) in vehicle treated mice (Figure 2E). This study has previously shown that sulprostone and other EP3 agonists cause a rise in MAP. The DG-041 treatment effectively blocked the sulprostone-evoked change in MAP (Figure 2E). In subsequent studies DG-041 was administered via SC injections at 20 mg/kg twice daily, which would provide plasma concentrations sufficient to achieve full coverage of the EP3 receptors. Reference: Prostaglandins Other Lipid Mediat. 2019 Oct; 144: 106353. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6778036/

	Solvent	mg/mL	mM	comments
Solubility
	DMSO	59.2	100.00

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 592.30 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Singh J, Zeller W, Zhou N, Hategan G, Mishra RK, Polozov A, Yu P, Onua E, Zhang J, Ramírez JL, Sigthorsson G, Thorsteinnsdottir M, Kiselyov AS, Zembower DE, Andrésson T, Gurney ME. Structure-activity relationship studies leading to the identification of (2E)-3-[l-[(2,4-dichlorophenyl)methyl]-5-fluoro-3-methyl-lH-indol-7-yl]-N-[(4,5-dichloro-2-thienyl)sulfonyl]-2-propenamide (DG-041), a potent and selective prostanoid EP3 receptor antagonist, as a novel antiplatelet agent that does not prolong bleeding. J Med Chem. 2010 Jan 14;53(1):18-36. doi: 10.1021/jm9005912. PMID: 19957930. 2. Heptinstall S, Espinosa DI, Manolopoulos P, Glenn JR, White AE, Johnson A, Dovlatova N, Fox SC, May JA, Hermann D, Magnusson O, Stefansson K, Hartman D, Gurney M. DG-041 inhibits the EP3 prostanoid receptor--a new target for inhibition of platelet function in atherothrombotic disease. Platelets. 2008 Dec;19(8):605-13. doi: 10.1080/09537100802351073. PMID: 19012178. 3. Ceddia RP, Downey JD, Morrison RD, Kraemer MP, Davis SE, Wu J, Lindsley CW, Yin H, Daniels JS, Breyer RM. The effect of the EP3 antagonist DG-041 on male mice with diet-induced obesity. Prostaglandins Other Lipid Mediat. 2019 Oct;144:106353. doi: 10.1016/j.prostaglandins.2019.106353. Epub 2019 Jul 2. PMID: 31276827; PMCID: PMC6778036. 4. Tilly P, Charles AL, Ludwig S, Slimani F, Gross S, Meilhac O, Geny B, Stefansson K, Gurney ME, Fabre JE. Blocking the EP3 receptor for PGE2 with DG-041 decreases thrombosis without impairing haemostatic competence. Cardiovasc Res. 2014 Mar 1;101(3):482-91. doi: 10.1093/cvr/cvt276. Epub 2013 Dec 9. PMID: 24323317.

In vitro protocol:

In vivo protocol:

1. Ceddia RP, Downey JD, Morrison RD, Kraemer MP, Davis SE, Wu J, Lindsley CW, Yin H, Daniels JS, Breyer RM. The effect of the EP3 antagonist DG-041 on male mice with diet-induced obesity. Prostaglandins Other Lipid Mediat. 2019 Oct;144:106353. doi: 10.1016/j.prostaglandins.2019.106353. Epub 2019 Jul 2. PMID: 31276827; PMCID: PMC6778036. 2. Tilly P, Charles AL, Ludwig S, Slimani F, Gross S, Meilhac O, Geny B, Stefansson K, Gurney ME, Fabre JE. Blocking the EP3 receptor for PGE2 with DG-041 decreases thrombosis without impairing haemostatic competence. Cardiovasc Res. 2014 Mar 1;101(3):482-91. doi: 10.1093/cvr/cvt276. Epub 2013 Dec 9. PMID: 24323317.

1: Tilly P, Charles AL, Ludwig S, Slimani F, Gross S, Meilhac O, Geny B, Stefansson K, Gurney ME, Fabre JE. Blocking the EP3 receptor for PGE2 with DG-041 decreases thrombosis without impairing haemostatic competence. Cardiovasc Res. 2014 Mar 1;101(3):482-91. doi: 10.1093/cvr/cvt276. PubMed PMID: 24323317. 2: Singh J, Zeller W, Zhou N, Hategan G, Mishra RK, Polozov A, Yu P, Onua E, Zhang J, Ramírez JL, Sigthorsson G, Thorsteinnsdottir M, Kiselyov AS, Zembower DE, Andrésson T, Gurney ME. Structure-activity relationship studies leading to the identification of (2E)-3-[l-[(2,4-dichlorophenyl)methyl]-5-fluoro-3-methyl-lH-indol-7-yl]-N-[(4,5-d ichloro-2-thienyl)sulfonyl]-2-propenamide (DG-041), a potent and selective prostanoid EP3 receptor antagonist, as a novel antiplatelet agent that does not prolong bleeding. J Med Chem. 2010 Jan 14;53(1):18-36. doi: 10.1021/jm9005912. PubMed PMID: 19957930. 3: Heptinstall S, Espinosa DI, Manolopoulos P, Glenn JR, White AE, Johnson A, Dovlatova N, Fox SC, May JA, Hermann D, Magnusson O, Stefansson K, Hartman D, Gurney M. DG-041 inhibits the EP3 prostanoid receptor--a new target for inhibition of platelet function in atherothrombotic disease. Platelets. 2008 Dec;19(8):605-13. doi: 10.1080/09537100802351073. PubMed PMID: 19012178.

View History

Dimethyl Isosorbide

MedKoo CAT#: 150143

CAS#: 5306-85-4